Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
Φόρτωση...
Ημερομηνία
Συγγραφείς
Aravantinos, G.
Bafaloukos, D.
Fountzilas, G.
Christodoulou, C.
Papadimitriou, C.
Pavlidis, N.
Kalofonos, H. P.
Gogas, H.
Kosmidis, P.
Dimopoulos, M. A.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Ann Oncol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. PATIENTS AND METHODS: Treatment consisted of vinorelbine 25 mg/m(2) as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m(2), as a 1-h i.v. infusion (day 8). Granulocyte colony-stimulating factor support was administered prophylactically on days 12-16. Treatment was repeated every 21 days. RESULTS: Forty-six patients were enrolled. The median number of previous chemotherapeutic regimens was one (range 1-3) with a median treatment-free interval of 4.3 months. Four chemotherapy cycles per patient were administered. Almost 75% of the planned doses for both drugs were given. Forty-one patients are evaluable for response. Three patients (6.5% of all patients; 7.3% of evaluable patients) achieved complete response and eight (17.4% and 19.5%, respectively) a partial response to chemotherapy, leading to overall response rates of 23.9% and 26.8%, respectively. Another 34.8% (39.0%) had stable disease. At a median follow-up of 30 months, the median disease-free survival was 13 months, relapse-free survival was 5 months, time to progression was 4.5 months, and overall survival was 9.3 months. Severe toxicities included leukopenia (31%), neutropenia (35%) and febrile neutropenia (20%). CONCLUSIONS: The combination of docetaxel/vinorelbine is an effective regimen with manageable toxicity for the treatment of platinum-resistant, paclitaxel-pretreated ovarian cancer.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Antineoplastic Agents/pharmacology, Antineoplastic Agents, Phytogenic/pharmacology, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Cisplatin/pharmacology, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Granulocyte Colony-Stimulating Factor/administration & dosage, Humans, Leukopenia/chemically induced, Middle Aged, Neoplasm Recurrence, Local/*drug therapy/pathology, Neutropenia/chemically induced, Ovarian Neoplasms/*drug therapy/pathology, Paclitaxel/administration & dosage/*analogs & derivatives/pharmacology, Prospective Studies, *Taxoids, Treatment Outcome, Vinblastine/administration & dosage/*analogs & derivatives
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/12853352
http://annonc.oxfordjournals.org/content/14/7/1094.full.pdf
http://annonc.oxfordjournals.org/content/14/7/1094.full.pdf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής